Base de dados : MEDLINE
Pesquisa : C11.187.781 [Categoria DeCS]
Referências encontradas : 2022 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 203 ir para página                         

  1 / 2022 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29230976
[Au] Autor:Lee JS; Ha SW; Yu S; Lee GJ; Park YJ
[Ad] Endereço:Cheil Eye Hospital, Daegu, Korea.
[Ti] Título:Efficacy and Safety of a Large Conjunctival Autograft for Recurrent Pterygium.
[So] Source:Korean J Ophthalmol;31(6):469-478, 2017 Dec.
[Is] ISSN:2092-9382
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To evaluate the efficacy and safety of pterygium excision using a large conjunctival autograft for the treatment of recurrent pterygium. METHODS: The medical records of 120 patients (126 eyes) with recurrent pterygium were reviewed. For each affected eye, pterygium excision with a large conjunctival autograft was performed. The graft was harvested from the superior bulbar area and measured more than 8 × 10 mm in size. Only patients who completed at least six months of follow-up were included. Postoperative clinical outcomes, recurrence rate, and complications were analyzed. Patients with any evidence of recurrence after surgery received a subconjunctival bevacizumab injection. RESULTS: The average patient age was 56.5 ± 10.2 years, and 45 out of 120 patients were male. The mean study follow-up period was 17.7 ± 17.6 months. Most patients were satisfied with the cosmetic outcome. Postoperative visual acuity improved from 0.69 to 0.75 (p < 0.05). Postoperative refractive astigmatism and corneal astigmatism decreased by 0.55 and 2.73 diopters, respectively (p < 0.05). The postoperative recurrence rate was 4.0%, and the average recurrence period was 7.4 ± 0.6 weeks. A subconjunctival injection of 5 mg bevacizumab was performed in cases of recurrence; no progression of the pterygium was observed following the injection. Postoperative complications included 2 cases of conjunctival graft edema in 2 eyes, 5 donor site scars in 5 eyes, 13 pyogenic granulomas in 13 eyes, and a conjunctival epithelial inclusion cyst in 7 eyes. CONCLUSIONS: Pterygium excision with a large conjunctival autograft for the treatment of recurrent pterygium produced an excellent cosmetic outcome, a low recurrence rate, and minimal complications. A subconjunctival bevacizumab injection given in cases of recurrence following surgery might be effective in preventing progression of the pterygium.
[Mh] Termos MeSH primário: Túnica Conjuntiva/transplante
Procedimentos Cirúrgicos Oftalmológicos/métodos
Pterígio/cirurgia
[Mh] Termos MeSH secundário: Autoenxertos
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Recidiva
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE
[do] DOI:10.3341/kjo.2016.0135


  2 / 2022 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29403336
[Au] Autor:Anderson EW; Dwarakanathan S; Haddadin R
[Ad] Endereço:Wake Forest Baptist Medical Center, Winston Salem, North Carolina.
[Ti] Título:Experimental use of an extracellular matrix graft in pterygium surgery.
[So] Source:Digit J Ophthalmol;23(4):15-17, 2017.
[Is] ISSN:1542-8958
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A 40-year-old man presented with a primary pterygium of the right eye and underwent pterygium excision using mitomycin C and placement of an extracellular matrix (ECM) adjuvant. As an adjuvant in pterygium surgery, ECM serves as a scaffold while promoting the growth of normal conjunctiva. Perioperatively, the ECM graft was found to be easily manipulated on the surgical field. It attached to the scleral bed with fibrin glue without complication. Postoperatively, there was no inflammation or local tissue reaction to the porcine ECM graft. At the most recent follow-up examination, 6 months postoperatively, there were no signs of recurrence of the pterygium past the limbus. This is the first report describing the use of ECM as an adjuvant to pterygium excision.
[Mh] Termos MeSH primário: Túnica Conjuntiva/cirurgia
Matriz Extracelular/transplante
Procedimentos Cirúrgicos Oftalmológicos/métodos
Pterígio/cirurgia
[Mh] Termos MeSH secundário: Adulto
Pálpebras/cirurgia
Seguimentos
Seres Humanos
Masculino
Transplante Autólogo
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180207
[St] Status:MEDLINE
[do] DOI:10.5693/djo.02.2017.11.001


  3 / 2022 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29443763
[Au] Autor:Zhang Z; Yang Z; Pan Q; Qin X; Deng Y; Cao Y
[Ad] Endereço:Jinhua Eye Hospital, Jinhua, ZheJiang.
[Ti] Título:Epibulbar complex cartilaginous choristoma: A distinctive clinicopathological case series and literature review.
[So] Source:Medicine (Baltimore);97(7):e9902, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To newly describe the clinical and histopathological characteristics of epibulbar complex cartilaginous choristoma incidentally observed in a series of pterygium excision patients.Noncomparative case series with chart review of 8 patients.During a 4-year period, we identified 8 cases of conventional unilateral nasal subpterygial cartilaginous choristoma in 1799 pterygium patients and analyzed their clinicopathological features. The incidence rate of this entity is 0.44% in pterygium patients. All of the cartilaginous choristomas were buried deep in the caruncle, covered by the pterygium, and embedded in tenon facia tissue. Its clinicopathological characteristics include hyaline cartilaginous tissue that is surrounded by fibrous connective tissue and smooth muscle bundles. S-100 protein-staining specifically revealed chondrocytes embedded within chondroid matrix.Epibulbar complex cartilaginous choristoma covered by pterygia and predominantly observed in the older population is rare. The lesions were buried deep in the caruncle, covered by the pterygium and embedded in tenon fascia tissue. These findings are inconsistent with those in previous reports.
[Mh] Termos MeSH primário: Coristoma
Túnica Conjuntiva
Procedimentos Cirúrgicos Oftalmológicos
Pterígio
[Mh] Termos MeSH secundário: Fatores Etários
China/epidemiologia
Coristoma/epidemiologia
Coristoma/patologia
Coristoma/cirurgia
Feminino
Seres Humanos
Cartilagem Hialina/patologia
Achados Incidentais
Masculino
Meia-Idade
Procedimentos Cirúrgicos Oftalmológicos/métodos
Procedimentos Cirúrgicos Oftalmológicos/estatística & dados numéricos
Pterígio/epidemiologia
Pterígio/patologia
Pterígio/cirurgia
Fatores de Risco
Proteínas S100/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (S100 Proteins)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009902


  4 / 2022 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28465659
[Au] Autor:Wang X; Zhang Y; Zhou L; Wei R; Dong L
[Ad] Endereço:Tianjin Medical University Eye Hospital, Tianjin Medical University Eye Institute, College of Optometry and Ophthalmology, Tianjin Medical University, Tianjin, People's Republic of China.
[Ti] Título:Comparison of fibrin glue and Vicryl sutures in conjunctival autografting for pterygium surgery.
[So] Source:Mol Vis;23:275-285, 2017.
[Is] ISSN:1090-0535
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To compare clinical parameters and the tear levels of inflammatory cytokines between pterygium surgery using sutures or fibrin glue. METHODS: Fifty-six patients with primary pterygium were divided into the suture group and the glue group, in which the autograft was secured with 10-0 Vicryl sutures and fibrin glue, respectively. A questionnaire, slit-lamp examination, Schirmer test, and visual acuity test were performed in all participants. Real-time quantitative PCR (q-PCR) was used to analyze the expression of genes in pterygium and healthy conjunctival tissues. Based on the qPCR results and literature reports, five inflammatory cytokines, including hepatocyte growth factor (HGF), fibroblast growth factor 2 (FGF2), transforming growth factor-ß1 (TGF-ß1), matrix metalloproteinase 2 (MMP2), and tumor necrosis factor-α (TNF-α), were selected, and their protein levels were measured with enzyme-linked immunosorbent assay (ELISA) in patient tears before surgery as well as at postoperative day 1, 7, and 30. RESULTS: There are 28 patients in either the suture or the glue group. The average duration of surgery was 20.17 ± 3.23 min for the glue group and 32.42 ± 4.47 min for the suture group (p = 0.000). Visual acuity in both groups was improved (p = 0.002) after the surgical procedures. There were more symptoms in the suture group than in the glue group at postoperative day 7 (p = 0.002). Postoperative symptoms disappeared in both groups at 1 month after surgery. Recurrence was observed in one case in the glue group and in two cases in the suture group at the 6 month postoperative follow-up (p = 0.714). In comparison to the preoperative levels (4.33 ± 0.43 ng/ml for the suture group; 4.20 ± 0.26 ng/ml for the glue group), the levels of TNF-α in tears increased in the suture group (5.02 ± 0.49 ng/ml, p = 0.016) and decreased in the glue group (3.84 ± 0.35 ng/ml, p = 0.052) on postoperative day 1. The glue treatment induced higher HGF production (4.78 ± 1.25 ng/ml) than the suture treatment (3.04 ± 1.18 ng/ml) at postoperative day 1 (p = 0.020). Higher levels of TGF-ß1 in the glue group were detected at postoperative day 1 (3.71 ± 0.18 ng/ml) and postoperative day 30 (4.50 ± 0.51 ng/ml), compared to those in the suture group, respectively (2.74 ± 0.21 ng/ml, p = 0.000 for day 1; 3.36 ± 0.96 ng/ml, p = 0.017 for postoperative day 30). CONCLUSIONS: Fibrin glue is effective and safe for attaching conjunctival autografts with an easy surgical procedure, shortened operating time, and less postoperative discomfort. In the early postoperative period, the protein expression of inflammatory cytokines implicates that fibrin glue may induce accelerated healing and subdued inflammation on the ocular surface compared to sutures.
[Mh] Termos MeSH primário: Túnica Conjuntiva/transplante
Adesivo Tecidual de Fibrina/uso terapêutico
Poliglactina 910
Pterígio/cirurgia
Técnicas de Sutura
Adesivos Teciduais/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Citocinas/genética
Ensaio de Imunoadsorção Enzimática
Feminino
Seres Humanos
Masculino
Meia-Idade
Procedimentos Cirúrgicos Oftalmológicos
Complicações Pós-Operatórias
Estudos Prospectivos
Pterígio/genética
RNA Mensageiro/genética
Reação em Cadeia da Polimerase em Tempo Real
Inquéritos e Questionários
Fatores de Tempo
Transplante Autólogo
Acuidade Visual
Técnicas de Fechamento de Ferimentos
Cicatrização/fisiologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cytokines); 0 (Fibrin Tissue Adhesive); 0 (RNA, Messenger); 0 (Tissue Adhesives); 34346-01-5 (Polyglactin 910)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE


  5 / 2022 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29178848
[Au] Autor:Zeng W; Liu Z; Dai H; Yan M; Luo H; Ke M; Cai X
[Ad] Endereço:Department of Ophthalmology, Zhongnan hospital of Wuhan University, No 169 Donghu road, Wuchang District, Wuhan, Hubei, 430071, People's Republic of China.
[Ti] Título:Anti-fibrotic, anti-VEGF or radiotherapy treatments as adjuvants for pterygium excision: a systematic review and network meta-analysis.
[So] Source:BMC Ophthalmol;17(1):211, 2017 Nov 25.
[Is] ISSN:1471-2415
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Anti-fibrotic, anti-VEGF (vascular endothelial growth factor) medications, or radiotherapy, as adjuvant for pterygium surgical procedure, has been suggested for reducing recurrence, but difficulties may be experienced in deciding which treatment to use. The purpose of this study was to compare the efficacies of these different adjuvants for preventing recurrence following pterygium surgery. METHODS: We conducted a systematic review to identify randomized controlled trials of patients with primary or recurrent pterygium who received anti-fibrotic, anti-VEGF medication, or radiotherapy as adjuvants in combination with surgical procedure. The surgical procedure contained bare sclera technique or petrygium excision combination with tissue grafting. The primary outcome of this study was recurrence. Direct-comparison and Bayesian network meta-analyses were performed to assess direct and indirect evidence of efficacy. RESULTS: We obtained data from 34 randomized controlled trials, representing a total of 2483 patients. Adjuvants included bevacizumab, 5-FU (5-fluorouracil), MMC (mitomycin C), and ß-RT (beta-radiotherapy). Compared with placebo, we found distinguishable improvement in recurrence with bevacizumab (odds ratio [OR] 0.38, 95% confidence interval [CI] 0.18-0.80), MMC (0.12, 95% CI 0.06-0.21), and ß-RT (0.17, 95% CI 0.04-0.69), but not with 5-FU (0.41, 95% CI 0.12-1.39). MMC significantly reduced recurrence when compared to bevacizumab (0.31, 95% CI 0.13-0.77) and 5-FU (0.28, 95% CI 0.08-0.99). The probability of having the most recurrences after excision was lowest for MMC, followed by bevacizumab and ß-RT. Similar results were found in subgroup analyses, including for primary pterygium, and the patients receiving bare sclera technique or conjunctival autograft. CONCLUSIONS: Adjuvants such as MMC, bevacizumab, and ß-RT could effectively prevent recurrence following pterygium excision. However, their efficacy and acceptability require further clarification in future randomized controlled trials.
[Mh] Termos MeSH primário: Inibidores da Angiogênese/uso terapêutico
Antifibrinolíticos/uso terapêutico
Pterígio/tratamento farmacológico
Radioterapia Adjuvante/métodos
[Mh] Termos MeSH secundário: Alquilantes/uso terapêutico
Quimioterapia Adjuvante
Seres Humanos
Procedimentos Cirúrgicos Oftalmológicos/métodos
Prevenção Primária/métodos
Pterígio/cirurgia
Ensaios Clínicos Controlados Aleatórios como Assunto
Recidiva
Prevenção Secundária/métodos
Fator A de Crescimento do Endotélio Vascular
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Alkylating Agents); 0 (Angiogenesis Inhibitors); 0 (Antifibrinolytic Agents); 0 (Vascular Endothelial Growth Factor A)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE
[do] DOI:10.1186/s12886-017-0601-5


  6 / 2022 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29049722
[Au] Autor:Nuwormegbe SA; Sohn JH; Kim SW
[Ad] Endereço:Department of Global Medical Science, Yonsei University, Wonju College of Medicine, Gangwon-do, Republic of Korea.
[Ti] Título:A PPAR-Gamma Agonist Rosiglitazone Suppresses Fibrotic Response in Human Pterygium Fibroblasts by Modulating the p38 MAPK Pathway.
[So] Source:Invest Ophthalmol Vis Sci;58(12):5217-5226, 2017 Oct 01.
[Is] ISSN:1552-5783
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose: Fibroblast activation may play an important role in pterygium progression. Synthetic peroxisome proliferator-activated receptor γ (PPAR-γ) ligands have been shown to be effective antifibrotic agents against transforming growth factor ß1 (TGF-ß1) induced fibrosis in several tissues. We aimed to investigate the antifibrotic effects of the PPAR-γ ligand rosiglitazone in pterygium fibroblasts and the underlying mechanisms. Methods: Profibrotic activation was induced by TGF-ß1 in primary cultured human pterygium fibroblasts and the effect of rosiglitazone treatment on α-smooth muscle actin (α-SMA), and extra cellular matrix proteins synthesis was detected by western blotting, real-time PCR, immunostaining, and flow cytometry. Pharmaceutical inhibition of PPAR-γ receptor was used to determine the dependency or otherwise of rosiglitazone's action on PPAR-γ signaling. Major signaling pathways downstream of TGF-ß1 were investigated by western blotting to assess their possible association with rosiglitazone's effect. Cell viability and apoptosis were investigated to assess drug-induced cytotoxicity, and the effect of rosiglitazone treatment on cell migration was further determined. Results: α-SMA and fibronectin synthesis induced by TGF-ß1 were suppressed by rosiglitazone treatment in a dose-dependent manner. Rosiglitazone also inhibited intrinsic TGF-ß1 expression. Smad2/3, ERK1/2, and P38 pathways were activated in response to TGF-ß1. Rosiglitazone suppressed TGF-ß1-induced P38 MAPK activation, while ERK1/2 and Smad2/3 signaling remained unaffected. The observed antifibrotic effect of rosiglitazone was not affected by the PPAR-γ antagonist GW9662, indicating it is not PPAR-γ dependent. Rosiglitazone also inhibited the proliferation and migration of pterygium fibroblasts. Conclusions: Rosiglitazone suppresses TGF-ß1-induced myofibroblast activation and extra cellular matrix synthesis in pterygium fibroblasts at least partly through the modulation of the p38 MAPK pathway.
[Mh] Termos MeSH primário: Hipoglicemiantes/farmacologia
Miofibroblastos/efeitos dos fármacos
PPAR gama/agonistas
Pterígio/tratamento farmacológico
Tiazolidinedionas/farmacologia
Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo
[Mh] Termos MeSH secundário: Actinas/metabolismo
Apoptose
Western Blotting
Células Cultivadas
Proteínas da Matriz Extracelular/metabolismo
Fibrose/prevenção & controle
Citometria de Fluxo
Técnica Indireta de Fluorescência para Anticorpo
Seres Humanos
Miofibroblastos/enzimologia
Miofibroblastos/patologia
Pterígio/enzimologia
Pterígio/patologia
Reação em Cadeia da Polimerase em Tempo Real
Transdução de Sinais
Fator de Crescimento Transformador beta1/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ACTA2 protein, human); 0 (Actins); 0 (Extracellular Matrix Proteins); 0 (Hypoglycemic Agents); 0 (PPAR gamma); 0 (Thiazolidinediones); 0 (Transforming Growth Factor beta1); 05V02F2KDG (rosiglitazone); EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171027
[Lr] Data última revisão:
171027
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171020
[St] Status:MEDLINE
[do] DOI:10.1167/iovs.17-22203


  7 / 2022 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29049230
[Au] Autor:You Z; Qin Y; Li G; Shi K
[Ad] Endereço:Department of Ophthalmology, the Second Affiliated Hospital, Nanchang University, Nanchang, Peoples' Republic of China.
[Ti] Título:Goniosynechialysis combined with cataract extraction for iridoschisis: A case report.
[So] Source:Medicine (Baltimore);96(42):e8295, 2017 Oct.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Iridoschisis is a rare eye disease. In this case report, we described the examination and diagnosis of a case of iridoschisis accompanied by secondary glaucoma. We also observed the effects of treating the patient with a combination of goniosynechialysis and cataract removal. PATIENT CONCERN: A 67-year-old female patient presented with decreased vision in both eyes. An eye examination indicated that visual acuities (VAs) were 20/100 and light perception in the right and left eyes, respectively. Both eyes exhibited shallow anterior chambers and narrow angles. The lower portion of the iris was loosened, and cable-like tissue was visible. The intraocular pressures in the right and left eyes were 22 mmHg and 58 mmHg, respectively. At the time of presentation, no medication was being used. DIAGNOSES: The patient was diagnosed with iridoschisis [oculus sinister (OU), indicates left eye], secondary glaucoma (OU), senile cataract (OU), and pterygium (oculus uterque, indicates both eyes). INTERVENTION: After relevant examinations were conducted, goniosynechialysis and phacoemulsification with intraocular lens implantation were performed on the right eye under local anesthesia. OUTCOMES: Two days after surgery, the right eye had VA of 20/40 and a transparent cornea. The anterior chamber was deeper, and intraocular pressure had decreased to 16 mmHg. Three months after surgery, the patient exhibited improved VA in the right eye and a lower IOP of 11 mmHg. LESSONS: Relative to other approaches, goniosynechialysis combined with cataract removal is a better treatment option for iridoschisis complicated with closed-angle glaucoma triggered by peripheral anterior synechiae.
[Mh] Termos MeSH primário: Extração de Catarata/métodos
Catarata/complicações
Glaucoma de Ângulo Fechado/complicações
Doenças da Íris/complicações
Doenças da Íris/cirurgia
[Mh] Termos MeSH secundário: Idoso
Feminino
Seres Humanos
Pterígio/complicações
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171122
[Lr] Data última revisão:
171122
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171020
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008295


  8 / 2022 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28873177
[Au] Autor:Meng Q; Qin Y; Deshpande M; Kashiwabuchi F; Rodrigues M; Lu Q; Ren H; Elisseeff JH; Semenza GL; Montaner SV; Sodhi A
[Ad] Endereço:Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.
[Ti] Título:Hypoxia-Inducible Factor-Dependent Expression of Angiopoietin-Like 4 by Conjunctival Epithelial Cells Promotes the Angiogenic Phenotype of Pterygia.
[So] Source:Invest Ophthalmol Vis Sci;58(11):4514-4523, 2017 Sep 01.
[Is] ISSN:1552-5783
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose: Disappointing results from clinical studies assessing the efficacy of therapies targeting vascular endothelial growth factor (VEGF) for the treatment of pterygia suggest that other angiogenic mediators may also play a role in its development. We therefore explore the relative contribution of VEGF, hypoxia-inducible factor (HIF)-1α (the transcription factor that regulates VEGF expression in ocular neovascular disease), and a second HIF-regulated mediator, angiopoietin-like 4 (ANGPTL4), to the angiogenic phenotype of pterygia. Methods: Expression of HIF-1α, VEGF, and ANGPTL4 were examined in surgically excised pterygia, and in immortalized human (ih) and primary rabbit (pr) conjunctival epithelial cells (CjECs). Endothelial cell (EC) tubule formation assays using media conditioned by ihCjECs in the presence or absence of inducers/inhibitors of HIF-1 or RNA interference (RNAi) targeting VEGF, ANGPTL4, or both were used to assess their relative contribution to the angiogenic potential of these cells. Results: HIF-1α and VEGF expression were detected in 6/6 surgically excised pterygia and localized to CjECs. Accumulation of HIF-1α in was confirmed in ihCjECs and prCjECs, including stratified prCjECs grown on collagen vitrigel, and resulted in expression of VEGF and the promotion of EC tubule formation; the latter effect was partially blocked using RNAi targeting VEGF mRNA expression. We demonstrate expression of a second HIF-regulated angiogenic mediator, ANGPTL4, in CjECs in culture and in surgically excised pterygia. RNAi targeting ANGPTL4 inhibited EC tubule formation and was additive to RNAi targeting VEGF. Conclusions: Our results support the development of therapies targeting both ANGPTL4 and VEGF for the treatment of patients with pterygia.
[Mh] Termos MeSH primário: Angiopoietinas/metabolismo
Túnica Conjuntiva/metabolismo
Subunidade alfa do Fator 1 Induzível por Hipóxia/fisiologia
Neovascularização Patológica/metabolismo
Pterígio/metabolismo
[Mh] Termos MeSH secundário: Moduladores da Angiogênese
Proteína 4 Semelhante a Angiopoietina
Angiopoietinas/genética
Animais
Western Blotting
Células Cultivadas
Digoxina/farmacologia
Endotélio Vascular/fisiologia
Ensaio de Imunoadsorção Enzimática
Células Epiteliais/metabolismo
Regulação da Expressão Gênica/fisiologia
Seres Humanos
Subunidade alfa do Fator 1 Induzível por Hipóxia/antagonistas & inibidores
Fenótipo
Interferência de RNA
RNA Mensageiro/genética
Coelhos
Reação em Cadeia da Polimerase em Tempo Real
Transfecção
Fator A de Crescimento do Endotélio Vascular/genética
Fator A de Crescimento do Endotélio Vascular/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ANGPTL4 protein, human); 0 (Angiogenesis Modulating Agents); 0 (Angiopoietin-like 4 Protein); 0 (Angiopoietins); 0 (HIF1A protein, human); 0 (Hypoxia-Inducible Factor 1, alpha Subunit); 0 (RNA, Messenger); 0 (VEGFA protein, human); 0 (Vascular Endothelial Growth Factor A); 73K4184T59 (Digoxin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170906
[St] Status:MEDLINE
[do] DOI:10.1167/iovs.17-21974


  9 / 2022 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28803935
[Au] Autor:Kim KW; Lee SJ; Kim JC
[Ad] Endereço:Graduate School of Chung-Ang University, College of Medicine, Seoul, Republic of Korea.
[Ti] Título:TNF-α upregulates HIF-1α expression in pterygium fibroblasts and enhances their susceptibility to VEGF independent of hypoxia.
[So] Source:Exp Eye Res;164:74-81, 2017 Nov.
[Is] ISSN:1096-0007
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The clinical manifestations of pterygium are characterized by rapid growth and postoperative recurrences. We had previously proposed that hypoxia-inducible factor (HIF)-1α recruits progenitor cells during the development and progression of pterygia. Recently, it was reported that various stimuli, including inflammation, could activate HIF-1α even under normoxic conditions. The ocular surface directly faces external environments, and is thus frequently exposed to inflammatory insults. First, we examined the gene expression of HIF-1α, its downstream molecule, vascular endothelial growth factor (VEGF)-A, and VEGF receptor (VEGFR)-2 in corneal and conjunctival cells compared with cultured human umbilical vein endothelial cells. Corneal fibroblasts had high expression of VEGFR-2 in the presence of TNF-α, and HIF-1α was activated by TNF-α in diverse ocular surface cells. The HIF-1α/VEGF/VEGFR signaling pathway in response to TNF-α was evaluated in cultured human pterygium fibroblasts (HPFs) at the gene and protein levels and was compared to treatment with cobalt chloride (CoCl ), a hypoxic mimetic, to exclude the effect of hypoxia. Although VEGF-A expression was not changed by TNF-α, expression of HIF-1α and VEGFR-2 was enhanced in HPFs treated with TNF-α, independent of hypoxia conditioning. In addition, VEGF-C gene expression was activated solely by TNF-α in HPF, but VEGF-B levels were not significantly affected. These results may provide mechanistic explanations for the uniquely vigorous proliferation of pterygium fibrovascular tissue during TNF-α-induced ocular surface inflammation.
[Mh] Termos MeSH primário: Fibroblastos/efeitos dos fármacos
Subunidade alfa do Fator 1 Induzível por Hipóxia/metabolismo
Pterígio/metabolismo
Fator de Necrose Tumoral alfa/farmacologia
[Mh] Termos MeSH secundário: Hipóxia Celular/fisiologia
Células Cultivadas
Córnea/citologia
Fibroblastos/metabolismo
Células Endoteliais da Veia Umbilical Humana
Seres Humanos
Hipóxia/metabolismo
RNA Mensageiro/metabolismo
Fator de Necrose Tumoral alfa/metabolismo
Regulação para Cima/efeitos dos fármacos
Fator A de Crescimento do Endotélio Vascular/metabolismo
Fator B de Crescimento do Endotélio Vascular/metabolismo
Fator C de Crescimento do Endotélio Vascular/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hypoxia-Inducible Factor 1, alpha Subunit); 0 (RNA, Messenger); 0 (Tumor Necrosis Factor-alpha); 0 (Vascular Endothelial Growth Factor A); 0 (Vascular Endothelial Growth Factor B); 0 (Vascular Endothelial Growth Factor C)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170815
[St] Status:MEDLINE


  10 / 2022 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28734814
[Au] Autor:Clearfield E; Hawkins BS; Kuo IC
[Ad] Endereço:Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University School of Medicine, Baltimore, Maryland.
[Ti] Título:Conjunctival Autograft Versus Amniotic Membrane Transplantation for Treatment of Pterygium: Findings From a Cochrane Systematic Review.
[So] Source:Am J Ophthalmol;182:8-17, 2017 Oct.
[Is] ISSN:1879-1891
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To summarize key findings from a systematic review of the effectiveness and risks of conjunctival autograft (CAG) compared with amniotic membrane transplant (AMT) for pterygium. DESIGN: Cochrane systematic review. METHODS: We included only randomized controlled trials (RCTs) in which CAG and AMT had been compared for primary or recurrent pterygia. The primary outcome was recurrence of pterygium ≥1 mm onto the cornea by 3 and 6 months post surgery. We adhered to Cochrane methods for trial selection, data extraction, risk of bias evaluation, and data synthesis. RESULTS: Twenty RCTs with 1866 participants (1947 eyes) were included. Pterygium recurrence 6 months after surgery ranged from 3.3% to 16.7% in the CAG group and 6.4% to 42.3% in the AMT group based on data from 1021 eyes in 10 RCTs. Estimated risk ratios from meta-analysis indicated that CAG-treated eyes had a 47% lower risk of recurrence 6 months after surgery compared with the AMT group (RR, 0.53, 95% confidence interval [CI], 0.33-0.85). For 96 eyes with recurrent pterygium, the risk of recurrence 6 months after CAG was reduced by 55% compared with AMT (risk ratio [RR], 0.45, 95% CI, 0.21-0.99). Three-month recurrence rates were similar for CAG and AMT based on data from 538 eyes (6 RCTs). CONCLUSIONS: CAG was more effective than AMT to prevent pterygium recurrence by 6 months post surgery, especially in recurrent pterygia. CAG-treated eyes had half the recurrence rates of AMT-treated eyes. Future RCTs should assess changes in patient-reported outcomes (symptoms, cosmesis) and visual acuity, and evaluate effects of surgical variations.
[Mh] Termos MeSH primário: Âmnio/transplante
Túnica Conjuntiva/transplante
Pterígio/cirurgia
[Mh] Termos MeSH secundário: Autoenxertos
Seres Humanos
Pterígio/fisiopatologia
Ensaios Clínicos Controlados Aleatórios como Assunto
Recidiva
Transplante Autólogo
Resultado do Tratamento
Acuidade Visual/fisiologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171003
[Lr] Data última revisão:
171003
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170724
[St] Status:MEDLINE



página 1 de 203 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde